Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Actavis First-To-Market with Generic Equivalents of Clobex® Shampoo and Clobex® Topical Lotion

January 3, 2012

MORRISTOWN, N.J., Jan. 3, 2012 /PRNewswire/ — Actavis Group, an international generic pharmaceuticals company, today announced that it has begun shipping Clobetasol Propionate Shampoo and Clobetasol Propionate Lotion, generic equivalents to Galderma’s Clobex(®) Shampoo and Clobex(®) Topical Lotion. Due to Actavis’ first-to-file status, the FDA has granted Actavis a 180-day marketing exclusivity.

Combined annual brand sales of Clobex Shampoo and Clobex Topical Lotion totaled $89.9 million for the 12 months ending September 30, 2011, according to IMS Health.

Commenting on the new approval, Doug Boothe, CEO of Actavis in the US, said:
“The launch of Clobetasol Propionate Shampoo and Clobetasol Propionate Lotion displays our continuing commitment to introduce new, high quality generic products to the marketplace, as well as highlights our expertise in developing and manufacturing a wide range of dosage forms. Actavis’ drive to be a leader in generic pharmaceuticals is supported by one of the largest product development pipelines in the industry.”

About Actavis:
Actavis Inc. is the U.S. subsidiary of Actavis Group hf. Approximately one third of Actavis’ sales are generated in North America, Actavis’ single largest market. Based in Morristown, NJ, Actavis has U.S. manufacturing and packaging facilities in Elizabeth, NJ; a manufacturing facility in Lincolnton, NC; and research and development facilities in Owings Mills, MD and Sunrise, FL. Please visit www.actavis.us for more information.

Clobex( )(®) is a registered trademark of a party other than Actavis.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.

SOURCE Actavis Group


Source: PR Newswire